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Correction
==========

Following publication of our article \[[@B1]\], we noticed two errors in Figure 3. Panel 3C, Con H3K4me2 was an erroneous duplication of panel 3D, Con H3K4me2 and the incorrect image was included for panel 3D, Con H3K9Ac. The results and conclusions are unaffected. The correct figure is given here as Figure [1](#F1){ref-type="fig"}.

![**Pargyline promotes inhibitory epigenetic modifications**. **(A)**MCF-7-PELP1 cells and **(B)**MCF-7-HER2 cells were treated with pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K4me2-specific, H3K9me2-specific or H3K9ac-specific antibodies and the status of epigenetic modifications was analyzed using real-time PCR with the estrogen receptor target gene GREB1C proximal promoter-specific primers (B). Immunohistochemistry analysis of indicated epigenetic marks was done on **(C)**MCF-7 and **(D)**MCF-7-PELP1 xenografts that were treated with or without pargyline. Representative images are shown. Quantitation of staining performed as described in Materials and methods. \*\*\*\**P*\< 0.0001, \*\*\**P*\< 0.001, \*\**P*\< 0.01, \**P*\< 0.05. PAR, pargyline; PELP1, proline glutamic acid and leucine-rich protein 1.](bcr3370-1){#F1}
